Cancer onset and progression involves disruptions of complex networks of biomolecular interactions in cells, as a result of genomic and epigenomic aberrations. To achieve a deeper understanding of the genetic basis of cancer and to identify novel translational directions requires moving beyond detecting simple associations between genomic aberrations and clinical endpoints. However, little is known about how the states of disease-perturbed regulatory networks are altered by such aberrations, or how aberrations ultimately lead to cellular dysfunction. The goal of the Center for Systems Analysis of the Cancer Regulome is to address this challenge by developing and applying advanced algorithms and model-based approaches to enable the interpretation of TCGA data at the level of regulatory mechanisms;and to use such knowledge for enabling principled and systematic approaches for drug target discovery and therapeutic intervention in a clinically relevant manner. The Center will build three computational pipelines that will carry out integrated analyses of TCGA-derived high-throughput experimental data sets. These pipelines will: 1) identify potential mechanisms of genomic-transcriptomic regulation associated with specific cancers and clinical parameters;2) infer networks that explain cancer type-specific transcriptional profiles, and identify molecules that may be important control nodes in these networks as a means to prioritize drug targets for therapeutic intervention;and 3) compare cancer-associated features across all cancer types within TCGA to gain insight into the regulatory basis for cancer progression in different cancer types. The results of these pipelines will be rapidly disseminated through TCGA, together with visualization tools that facilitate the exploration and evaluation of each derived regulatory mechanism.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Resource-Related Research Projects--Cooperative Agreements (U24)
Project #
5U24CA143835-02
Application #
7942769
Study Section
Special Emphasis Panel (ZCA1-SRLB-U (O1))
Program Officer
Lee, Jerry S
Project Start
2009-09-28
Project End
2014-07-31
Budget Start
2010-08-01
Budget End
2011-07-31
Support Year
2
Fiscal Year
2010
Total Cost
$1,527,337
Indirect Cost
Name
Institute for Systems Biology
Department
Type
DUNS #
135646524
City
Seattle
State
WA
Country
United States
Zip Code
98109
Hmeljak, Julija; Sanchez-Vega, Francisco; Hoadley, Katherine A et al. (2018) Integrative Molecular Characterization of Malignant Pleural Mesothelioma. Cancer Discov 8:1548-1565
Sanchez-Vega, Francisco; Mina, Marco; Armenia, Joshua et al. (2018) Oncogenic Signaling Pathways in The Cancer Genome Atlas. Cell 173:321-337.e10
Way, Gregory P; Sanchez-Vega, Francisco; La, Konnor et al. (2018) Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas. Cell Rep 23:172-180.e3
Ricketts, Christopher J; De Cubas, Aguirre A; Fan, Huihui et al. (2018) The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. Cell Rep 23:313-326.e5
Knijnenburg, Theo A; Wang, Linghua; Zimmermann, Michael T et al. (2018) Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep 23:239-254.e6
Peng, Xinxin; Chen, Zhongyuan; Farshidfar, Farshad et al. (2018) Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers. Cell Rep 23:255-269.e4
Huang, Kuan-Lin; Mashl, R Jay; Wu, Yige et al. (2018) Pathogenic Germline Variants in 10,389 Adult Cancers. Cell 173:355-370.e14
Ding, Li; Bailey, Matthew H; Porta-Pardo, Eduard et al. (2018) Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics. Cell 173:305-320.e10
Seiler, Michael; Peng, Shouyong; Agrawal, Anant A et al. (2018) Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. Cell Rep 23:282-296.e4
Liu, Yang; Sethi, Nilay S; Hinoue, Toshinori et al. (2018) Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas. Cancer Cell 33:721-735.e8

Showing the most recent 10 out of 112 publications